Status
Conditions
Treatments
About
The purpose is to test the safety and effectiveness of intravenous ribavirin therapy in persons with suspected and subsequently proven hantavirus infection. The hantavirus is spread through the air into the lungs when dry rodent feces are moved or disturbed. It is characterized by fever and bleeding.
Full description
Patients are randomized to receive either ribavirin or a placebo for 7 days. At the completion of therapy, patients will be seen on follow-up visits on days 14, 28, and 84.
Sex
Ages
Volunteers
Inclusion criteria
You may be eligible for this study if you:
Exclusion criteria
You will not be eligible for this study if you:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal